Developments in 177Lu-based radiopharmaceutical therapy and dosimetry

Frontiers in Chemistry

Chemistry

Siju C. George¹  E. James Jebaseelan Samuel² 

[1] Radiation Oncology Department, Miami Cancer Institute, Baptist Health, Miami, FL, United States;Vellore Institute of Technology, Vellore, India;Vellore Institute of Technology, Vellore, India;

关键词: Lu;    absorbed dose;    patient-specific dosimetry;    dose calculations;    imaging;    calculation methods;    clinical trials;    contemporary developments;   

DOI  :  10.3389/fchem.2023.1218670

 received in 2023-05-07, accepted in 2023-06-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

177Lu is a radioisotope that has become increasingly popular as a therapeutic agent for treating various conditions, including neuroendocrine tumors and metastatic prostate cancer. 177Lu-tagged radioligands are molecules precisely designed to target and bind to specific receptors or proteins characteristic of targeted cancer. This review paper will present an overview of the available 177Lu-labelled radioligands currently used to treat patients. Based on recurring, active, and completed clinical trials and other available literature, we evaluate current status, interests, and developments in assessing patient-specific dosimetry, which will define the future of this particular treatment modality. In addition, we will discuss the challenges and opportunities of the existing dosimetry standards to measure and calculate the radiation dose delivered to patients, which is essential for ensuring treatments’ safety and efficacy. Finally, this article intends to provide an overview of the current state of 177Lu- tagged radioligand therapy and highlight the areas where further research can improve patient treatment outcomes.

【 授权许可】

Unknown   
Copyright © 2023 George and Samuel.